Impact of Intravenous Lidocaine During Colorectal Surgery on Pain and Immune Functions

PHASE4RecruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

April 29, 2019

Primary Completion Date

December 31, 2024

Study Completion Date

June 30, 2025

Conditions
Intravenous Lidocaine and Immunity
Interventions
DRUG

intravenous lidocaine (IVL)

lidocaine 2% will be used for induction (1 syringe of 5 ml, administered dose of 1.5 mg / kg) and for intra-operative infusion (1 syringe of 30 ml, infusion dose of 1.5 mg / kg / h). Lidocaine syringes and placebo will be prepared on a blinded manner so that the investigating anesthesiologist in charge of the patient in the operating room, as well as the respiratory therapist and the recovery room nurse and the floors do not know what the patient received during the anesthesia (whether IVL or placebo).

OTHER

Placebo

Group Control will receive (double blinded) an infusion of saline at the same volume and regimen than the lidocaine 2% group (IVL).

Trial Locations (1)

H1T2M4

RECRUITING

Hôpital Maisonneuve-Rosemont, CIUSSS de l'Est de l'Ile de Montréal, Montreal

All Listed Sponsors
collaborator

Foundation of Anesthesia and Resuscitation of Quebec

UNKNOWN

lead

Ciusss de L'Est de l'Île de Montréal

OTHER